Martingale Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Martingale Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.45M	Buy	139,535 +19,852	+17%	+$473K	0.09%	226
2025 Q4	$2.79M	Sell	119,683 -715	-0.6%	-$15.9K	0.07%	249
2025 Q3	$2.37M	Buy	120,398 +8,058	+7%	+$166K	0.06%	273
2025 Q2	$2.44M	Buy	112,340 +23	+0%	+$543	0.06%	265
2025 Q1	$2.72M	Buy	112,317 +1,350	+1%	+$30.4K	0.07%	228
2024 Q4	$2.32M	Buy	110,967 +23,890	+27%	+$513K	0.06%	280
2024 Q3	$1.73M	Buy	+87,077	New	+$1.61M	0.04%	347
2022 Q4	–	Sell	-56,476	Closed	-$725K	–	835
2022 Q3	$725K	Sell	56,476 -45,226	-44%	-$536K	0.01%	534
2022 Q2	$714K	Buy	+101,702	New	+$746K	0.01%	563

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Martingale Asset Management's CPRX Position: Q1 2026 in Review

Martingale Asset Management increased its Catalyst Pharmaceutical (CPRX) stake by 17% in Q1 2026, buying an estimated $473K and bringing the position to 139,535 shares worth $3.45M. The position accounts for 0.09% of the portfolio, ranked #226.

Martingale Asset Management first reported a position in CPRX in Q2 2022 and has held it in 9 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Martingale Asset Management held 139,535 shares of Catalyst Pharmaceutical worth $3.45M as of Q1 2026.
Martingale Asset Management bought 19,852 Catalyst Pharmaceutical shares in Q1 2026, an estimated $473K.
Catalyst Pharmaceutical made up 0.09% of Martingale Asset Management's portfolio in Q1 2026, its #226 holding.
Martingale Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 9 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.